Katrine Bosley is former CEO of Editas Medicines and Avila Therapeutics. She discusses growing up in Ohio, her first job in biotech (as an administrative assistant) and why her five years at CRISPR company Editas felt more like 1,000. This episode is part of Nature Biotechnology's focus issue on translating the CRISPR technology.  See acast.com/privacy for privacy and opt-out information.

Nature Biotechnology Podcast

Katrine Bosley

Ted Love is the president and CEO of Global Blood Therapeutics. In his conversation with Nature Biotechnology, he discusses why his time at Haverford College was transformative, why he views Global Blood Therapeutics as a social justice company, and what might be gained from the “racial catharsis” happening in America after the police killing of George Floyd.  See acast.com/privacy for privacy and opt-out information.

Ted Love

Alexis Borisy is CEO and Chairman of EQRx, and a long-time biotech builder with Third Rock Ventures. His conversation with Nature Biotechnology covers growing up as a “faculty brat” in Wisconsin, dropping out of his PhD program at Harvard and why, even as an investor, biotech cannot be all about the money.   See acast.com/privacy for privacy and opt-out information.

Alexis Borisy

A conversation with Jeremy Levin, chairman of the Biotechnology Innovation Organization and CEO of Ovid Therapeutics, about industry versus government responses to covid19, the split within biotech on how to address charges of high prices, and why the biopharma industry is so disliked.   See acast.com/privacy for privacy and opt-out information.

Bonus: Jeremy Levin

Bassil Dahiyat is co-founder, president and CEO of Xencor. His conversation with Nature Biotechnology covers his parents emigrating from Jordan, how Xencor has survived (and changed) over the past 22 years, and when it’s necessary for a CEO to speak out. For information regarding your data privacy, visit acast.com/privacy

Bassil Dahiyat

Senior Editor Irene Jarchum talks to Stefan Schneeberger about the significance of a recent Nature Biotechnology paper describing a sophisticated perfusion machine to keep human livers alive for a week. The work was carried out by Pierre-Alain Clavien and colleagues from ETH Zurich. Read the paper here. For information regarding your data privacy, visit acast.com/privacy

Forum: Schneeberger on Clavien

Greg Verdine is a professor at Harvard University, and CEO and president of FogPharma and LifeMine Therapeutics. He is co-founder of more than 10 companies. His talk with Nature Biotechnology covers growing up in the Pine Barrens of New Jersey, the importance of excelling in the lab versus the classroom, and drugging the undruggable.  For information regarding your data privacy, visit acast.com/privacy

First Rounders: Greg Verdine

Samantha Du is founder, CEO and chairman of Zai Lab. In her conversation with Nature Biotechnology she discusses her thoughts on the US-China trade war, what makes Zai Lab a success, and her family's experience during the Cultural Revolution in China.

First Rounders: Samantha Du

Pardis Sabeti is a co-founder of Sherlock Biosciences, the head of the Sabeti Lab, and a co-author of Outbreak Culture. Her conversation with Nature Biotechnology covers her family fleeing the Iranian revolution, the Sabeti Lab's role in the Ebola outbreak of 2014-2016, and the ATV accident that nearly killed her.

First Rounders: Pardis Sabeti

Nina Tandon is co-founder and CEO of EpiBone. Her First Rounders conversation covers growing up on Roosevelt Island in New York City, witnessing September 11, and tackling her company's first Phase 1 trial.

First Rounders: Nina Tandon

Cigall Kadoch is a co-founder of Foghorn Therapeutics and assistant professor at the Dana-Farber Cancer Institute, where she runs the Kadoch lab. In her talk with Nature Biotechnology, she discusses launching Foghorn, how geography affects biotech success, and the link between interior design and scientific rigor.

First Rounders: Cigall Kadoch

Robert Langer is the David H. Koch Institute professor at the Massachusetts Institute of Technology. He also runs the Langer Lab and is co-founder of more than 40 biotech companies. His talk with Nature Biotechnology covers the death of his father, his experience teaching high school science and math, and the requirements for launching a successful biotech.

First Rounders: Robert Langer

George Church is professor of genetics at Harvard University, and professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology. He is also co-founder of more than 20 biotech companies. His talk with Nature Biotechnology covers being held back in 9th grade, launching the Human Genome Project, and the necessity of surveilling synthetic biologists.

First Rounders: George Church

George Church is professor of genetics at Harvard University, and professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology. He is also co-founder of more than 20 biotech companies. His talk with covers being held back in 9 grade, launching the Human Genome Project, and the necessity of surveilling synthetic biologists.

Chad Womack is senior director of STEM initiatives at UNCF. The episode covers Womack's path to HIV research at Harvard, his experience founding a biotech just before the Great Recession, and what the election of President Barack Obama meant to African Americans.

First Rounders: Chad Womack

Nature Biotechnology podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.

hubhopper

Nature Biotechnology Podcast

hubhopper